Derek Crowther
#162,751
Most Influential Person Now
Derek Crowther's AcademicInfluence.com Rankings
Derek Crowtherlaw Degrees
Law
#2791
World Rank
#3469
Historical Rank
Common Law
#149
World Rank
#161
Historical Rank
International Law
#793
World Rank
#966
Historical Rank
Derek Crowtherengineering Degrees
Engineering
#7080
World Rank
#8441
Historical Rank
Biomedical Engineering
#680
World Rank
#692
Historical Rank
Electrical Engineering
#2178
World Rank
#2284
Historical Rank
Download Badge
Law Engineering
Derek Crowther's Degrees
- PhD Biomedical Engineering University of California, San Francisco
- Masters Biomedical Engineering University of California, San Francisco
- Bachelors Biomedical Engineering University of California, San Francisco
Why Is Derek Crowther Influential?
(Suggest an Edit or Addition)Derek Crowther's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A predictive model for aggressive non-Hodgkin's lymphoma. (1993) (4400)
- Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. (1989) (1526)
- Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data (1997) (832)
- Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. (1994) (559)
- Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. (1987) (520)
- Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. (1999) (512)
- Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. (1992) (440)
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. (1991) (307)
- Failure to preserve fertility in patients with Hodgkin's disease (2004) (255)
- The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. (1989) (250)
- CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. (1998) (246)
- Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. (1998) (240)
- Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of (2000) (226)
- The effect of combination chemotherapy on ovarian function in women treated for hodgkin's disease (1983) (223)
- Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. (1998) (212)
- The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male (1982) (206)
- In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. (1988) (183)
- The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. (1988) (179)
- Immunotherapy for Acute Myelogenous Leukaemia (1973) (177)
- Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. (1978) (154)
- Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. (1993) (152)
- MVPP chemotherapy regimen for advanced Hodgkin's disease (1978) (145)
- A phase I study of intravenous bryostatin 1 in patients with advanced cancer. (1993) (139)
- A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. (1995) (139)
- Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen. (1995) (137)
- Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (1993) (133)
- Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis (1993) (121)
- Combination chemotherapy for acute lymphoblastic leukaemia in adults. (1978) (118)
- Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. (1996) (100)
- Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records (1997) (98)
- Maintenance chlorambucil after CVP in the management of advanced stage, low‐grade histologic type non‐Hodgkin's lymphoma: A randomized prospective study with an assessment of prognostic factors (1988) (97)
- High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. (1998) (96)
- 5T4 oncofetal antigen expression in ovarian carcinoma (1994) (94)
- Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. (1994) (92)
- Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. (1989) (89)
- Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. (1977) (87)
- Malignant melanoma in children and adolescents (1981) (86)
- The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. (1989) (84)
- ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. (2002) (82)
- Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. (1989) (82)
- Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. (1993) (80)
- Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. (1988) (80)
- Immunotherapy for acute myelogenous leukemia. (1975) (74)
- CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN FOR BREAST CANCER (1983) (72)
- Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. (1994) (70)
- Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. (1996) (66)
- Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. (1991) (65)
- A method for following human lymphocyte traffic using indium-111 oxine labelling. (1981) (65)
- A prospective study of the treatment of high-grade histology non-Hodgkin's lymphoma involving the gastrointestinal tract. (1985) (62)
- Factors influencing prognosis in adults with acute myelogenous leukaemia. (1975) (59)
- Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. (1998) (58)
- Haemopoietic cell kinetics in humans treated with rGM‐CSF (1992) (57)
- Viridans streptococcal bacteraemia in patients with haematological and solid malignancies. (1991) (54)
- Relationship between the pretreatment proliferative activity of marrow blast cells and prognosis of acute lymphoblastic leukaemia of childhood (1980) (52)
- Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres. (1988) (52)
- Metallothionein levels in ovarian tumours before and after chemotherapy. (1991) (51)
- Activity of JM9 in advanced ovarian cancer: a phase I-II trial. (1985) (51)
- A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease. (1984) (51)
- Spinal-cord compression in myeloma. (1979) (47)
- Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. (1988) (47)
- Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. (1990) (45)
- DNA content in high and intermediate grade non-Hodgkin's lymphoma-prognostic significance and clinicopathological correlations. (1989) (45)
- Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. (1995) (45)
- Combined modality management of local and disseminated adult soft tissue sarcomas: a review of 257 cases seen over 10 years at the Christie Hospital & Holt Radium Institute, Manchester. (1985) (44)
- A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. (1989) (43)
- Human lymphocyte traffic assessed by indium-111 oxine labelling: clinical observations. (1981) (42)
- Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. (1998) (41)
- Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. (1990) (41)
- Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer--a phase I toxicity study and pharmacokinetic analysis. (1993) (40)
- Report of the first workshop on prognostic factors in large-cell lymphomas. (1991) (40)
- Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. (1994) (40)
- Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. (1992) (38)
- Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5‐fluorouracil, methotrexate, and vitamin A (1980) (35)
- Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma. (1983) (34)
- A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. (1993) (33)
- VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. (1983) (32)
- Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. (1994) (32)
- Cancer—Principles and Practice of Oncology. V (1982) (32)
- The pre-treatment proliferative activity of non-Hodgkin's lymphoma cells. (1981) (31)
- Carcinosarcoma of the ovary treated over a 10-year period at the Christie Hospital (1993) (30)
- Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. (1995) (30)
- The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: a report from the Manchester Lymphoma Group. (1985) (29)
- A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma. (1984) (29)
- Factors affecting remission and survival in patients with advanced hodgkin's disease treated with MVPP (1986) (29)
- VAD chemotherapy—toxicity and efficacy—in patients with multiple myeloma and other lymphoid malignancies (1987) (27)
- Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours (2011) (27)
- Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. (1995) (27)
- Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome. (1996) (26)
- Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. (1997) (25)
- A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up. (1991) (25)
- Anti‐T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy—changes in serum levels following C parvum, BCG immunization (1980) (25)
- Prognostic factors in stage I and II high and intermediate grade non-Hodgkin's lymphoma. (1988) (24)
- The Migratory Properties of Indium‐111 Oxine Labelled Lymphocytes in Patients with Chronic Lymphocytic Leukaemia (1981) (24)
- Early central nervous system involvement in adults with acute non-myelogenous leukaemia. (1977) (24)
- Expression of O6-alkylguanine-DNA-alkyltransferase in situ in ovarian and Hodgkin's tumours. (1993) (23)
- Effects of erythropoietin on mobilisation of haemopoietic progenitor cells. (1994) (23)
- Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma (1990) (23)
- Phase I-II evaluation of acronine in patients with multiple myeloma. (1983) (22)
- Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress. (1991) (22)
- Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA) in cancer patients (2004) (20)
- Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. (1977) (20)
- Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions. (1979) (19)
- The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function. (1990) (19)
- Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma. (A report of 89 cases with extensive disease from the Manchester Lymphoma Group). (1980) (19)
- Cancer Therapy: Prognostic Factors and Criteria of Response (1977) (19)
- Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma. (1994) (18)
- Intermittent high‐dose cyclophosphamide with and without prednisolone. A study of the relationships between toxicity, response and survival in metastatic lung cancer (1982) (18)
- A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. (1996) (18)
- Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro (1994) (17)
- A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies. (1993) (17)
- Lymphocyte migration in malignant disease. (1983) (17)
- Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. (1998) (16)
- Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation. (1992) (16)
- The management of primary fallopian tube carcinoma (1990) (16)
- 11-WEEK COURSE OF SEQUENTIAL METHOTREXATE, THORACIC IRRADIATION, AND MODERATE-DOSE CYCLOPHOSPHAMIDE FOR "LIMITED"-STAGE SMALL-CELL BRONCHOGENIC CARCINOMA A Study from the Manchester Lung Tumour Group (1982) (16)
- Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide, and etoposide. (1985) (14)
- EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma (1997) (14)
- An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP. (1991) (14)
- Serum β2-microglobulin in patients with non-Hodgkin's lymphoma (1983) (13)
- A phase I and pharmacokinetic study of amphethinile. (1988) (13)
- Treatment of relapsed Hodgkin's disease using a weekly chemotherapy of short duration: results of a pilot study in 20 patients. (1991) (13)
- Tamoxifen in the treatment of metastatic malignant melanoma. (1982) (12)
- Bone marrow involvement in adult soft tissue sarcomas. (1982) (12)
- Immunotherapy of Acute Myeloblastic Leukemia in Man (1974) (12)
- In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with ma (2004) (12)
- The management of Hodgkin's disease. (1993) (11)
- New approaches to the management of patients with non-Hodgkin's lymphoma of high-grade pathology. First Gordon Hamilton-Fairley memorial lecture. (1981) (11)
- Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytes. (1994) (10)
- Clinical studies with recombinant human granulocyte-macrophage colony-stimulating factor. (1990) (10)
- Studies of lectin binding to normal and neoplastic lymphoid tissues. I. Normal nodes and Hodgkin's disease. (1982) (10)
- Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease (2004) (10)
- High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. (1998) (10)
- A reliable approach for sequencing clone-specific CDRIII regions in B-cell lymphoma. (1994) (10)
- Colchicine ultrasensitivity of peripheral-blood lymphocytes from patients with non-Hodgkin's lymphoma. (1980) (10)
- Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations. (1979) (10)
- Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer. (1984) (10)
- Changes in cellular immunity following nephrectomy for localized and metastatic hypernephroma. (1977) (9)
- A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma (2004) (9)
- Effects of Corynebacterium parvum on cellular immunity of cancer patients, assayed sequentially over 63 days (1981) (9)
- Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions. (1979) (9)
- Phase I study of recombinant DNA granulocyte macrophage colony stimulating factor. (1988) (9)
- Serum glycoprotein hormone alpha sub-unit values and survival in metastatic melanoma patients. (1979) (9)
- The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma. (1999) (9)
- STAGTING PATIENTS WITH NON‐HODGKIN'S LYMPHOMA (1982) (9)
- c-kit receptors in ovarian tumors and the response of ovarian carcinoma cell lines to recombinant human stem cell factor (1995) (9)
- Management of high-grade non-Hodgkin's lymphoma in adults. (1987) (9)
- The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. (1993) (9)
- A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours (2004) (8)
- Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor (1992) (8)
- The “Hot spleen” phenomenon in metastatic malignant melanoma. Its incidence and relationship with the immune system (1982) (8)
- Effects of diphenylhydantoin on killer cell activity and other immunological functions. A sequential study including the interaction of Corynebacterium parvum in melanoma patients. (1982) (8)
- Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma? (1997) (8)
- Short report: Weekly oral 4-demethoxydaunorubicin in patients with relapsed low grade non-Hodgkin's lymphoma (1991) (8)
- Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1. (1994) (8)
- Correlation of drug resistance-associated parameters in ovarian tumor biopsies (1993) (8)
- The effect of the GM‐CSF/IL‐3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer (1996) (7)
- Comparative intraperitoneal pharmacokinetics of three platinum analogues (2004) (7)
- Blood clearance of three radioactively labelled platinum complexes, in patients with malignant disease. (1982) (7)
- The behavior of autologous indium-114m-labeled lymphocytes in patients with lymphoid cell malignancy. (1988) (7)
- Ultrastructural aspects of colchicine ultrasensitivity in CLL lymphocytes. (1981) (7)
- Lymphocyte function in the blood of patients with untreated non-Hodgkin lymphoma: influence of stage and pathology. (1977) (7)
- In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue (2004) (7)
- A method for studying the dynamics of the primary migration of human lymphocytes using Indium-iii oxine cell labelling. (1982) (7)
- A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide. (1996) (6)
- Interferon in the treatment of multiple myeloma and the non-Hodgkin's lymphomas. (1985) (6)
- Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients. (1977) (6)
- Autologous lymphocytes as vectors to target therapeutic radiation, using indium‐114m, in patients with lymphoid cell malignancy (2002) (5)
- The role of computed tomography in the management of ovarian tumours of borderline malignancy. (1997) (5)
- Primary Carcinoma of the Fallopian Tube: Favourable Response to New Chemotherapeutic Agent, CHIP (1985) (4)
- Treatment of lymphoid cell malignancy with In-114m labelled autologous lymphocytes. (1997) (4)
- Weekly oral 4-demethoxydaunorubicin in patients with relapsed low grade non-Hodgkin's lymphoma. (1991) (4)
- Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations. (1979) (4)
- Surgery and Radiotherapy in the Treatment of Primary Carcinoma of the Fallopian Tube – Report of 18 Cases (1985) (4)
- A phase I toxicity study of human rDNA interferon in patients with solid tumours (2004) (4)
- Lack of prognostic value of the thymidine-labelling index in adult acute leukaemia. (1981) (4)
- Relationship between 06-alkylguanine-DNA alkyltransferase levels and 06-methyldeoxyguanosine formation in peripheral blood cells of patients receiving CBI0-277. (1994) (3)
- Have interferons a clinical role in the management of patients with cancer (1986) (3)
- Medical Oncology: An Advanced Course (1981) (3)
- The role of postoperative alkylating agent therapy in early‐stage epithelial ovarian cancer (1989) (3)
- Treatment of acute myelogenous leukaemia in adults. (1971) (3)
- Towards quality control in cancer chemotherapy. (1996) (3)
- Medical Oncology: Medical Aspects of Malignant Disease (1975) (3)
- 114Inm oxine-labelled lymphocytes--therapeutic applications. (1988) (3)
- Phase I clinical trial of methylene dimethane sulfonate. (1987) (3)
- Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin. (1981) (3)
- Combination chemotherapy for advanced non-Hodgkin's lymphoma of unfavourable histology (2004) (3)
- IP versus IV Pharmacokinetics in Patients Using Radiolabelled Paraplatin (1988) (3)
- Studies of lectin binding to normal and neoplastic lymph nodes. II. Non-Hodgkin's lymphoma. (1982) (2)
- Gastrointestinal involvement with myeloma. (1983) (2)
- Lymphocyte function related to survival curves in patients with metastatic melanoma treated by chemoimmunotherapy. (1978) (2)
- Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma. (1983) (2)
- Phase II Evaluation in Patients with Non-Hodgkin’s Lymphoma the Old World Experience — An Interim Report (1985) (2)
- Cancer Chemotherapy—Its role in the Treatment Strategy of Haematologic Malignancies and Solid Tumours (1977) (2)
- Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group. (1992) (2)
- Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma. (1992) (2)
- Formation and loss of 06-methyldeoxyguanosine (06-MedG) in peripheral leukocytes of patients receiving dacarbazine (DTIC) or CB 10-277. (1993) (2)
- Blood clearance of radioactively labelled CBDCA in cancer patients. (1983) (2)
- The behaviour of autologus In-114m labelled lymphocytes in patients with lymphoid cell malignancy. (1988) (2)
- Increased Numbers of Progenitor Cells in the Apheresis Product of Patients Randomised to Receive Increasing Doses of Stem Cell Factor (r-metHuSCF) Administered in Combination with Chemotherapy and a Standard Dose of Filgrastim (r-metHuG-CSF) (1998) (1)
- EXPRESSION OF O(6)-ALKYLGUANINE-DNA-ALKYLTRANSFERASE INSITU IN OVARIAN AND HODGKINS TUMORS (1993) (1)
- Is obtention of partial response (PR) in front line chemotherapy critical to improve outcome of metastatic soft tissue sarcoma (MSTS) patients (pts) (1998) (1)
- In vivo distribution studies of radioactively labelled platinum complexes in patients with malignant disease, using a gamma-camera. (1985) (1)
- Authors' reply (1989) (1)
- Clinical oncology: case presentations from oncology centres. Intensive treatment of poor prognosis gastrointestinal lymphoma. (1992) (1)
- VAPEC B: a weekly chemotherapy for high grade non-Hodgkin's lymphoma. Early results of a collaborative trial at two centres. (1990) (1)
- The role of postoperative alkylating agent therapy in earlystage epithelial ovarian cancer (1989) (1)
- Changes in nonspecific lymphoid (NK, K, T cell) cytotoxicity following BCG immunisation of healthy subjects (2004) (1)
- Chemotherapy (MVPP) for Stage IIIB/IV Hodgkin’s disease with an assessment of prognostic factors (1985) (1)
- Lymphocyte Cytotoxicity in Melanoma Patients Undergoing Immunotherapy (1979) (1)
- Peripheral blood progenitor cell (PBPC) transplantation with a single apheresis (1993) (1)
- Effects of intermittent 5-fluorouracil and adriamycin on various immune parameters in carcinoma patients with reference to the tumour load (1977) (1)
- Chemotherapy of Cancer Dissemination and Metastasis (1976) (1)
- An Introduction to Cancer Medicine (1979) (1)
- Controversies in Oncology (1982) (1)
- TRENDS AND SOCIO-ECONOMIC INEQUALITIES IN CANCER SURVIVAL OF PATIENTS WITH HODGKIN’S DISEASE DIAG- NOSED IN ENGLAND AND WALES BETWEEN 1986 AND 1999 (2005) (0)
- Effect of verapamil on daunorubicin accumulation in lymphocytes isolated from patients undergoing chemotherapy (2004) (0)
- The pharmacokinetics of In-114m labelled lymphocytes: A potential agent for selective internal irradiation of lymphoid tissue. (1986) (0)
- Leukaemia and lymphoma: Reviews 1, A. Polliack (Ed.). Harwood Academic Publishers (1992), 3 7186 5251 X E36.00,$68.00 (1993) (0)
- Lymphocyte migration inmalignant disease (1983) (0)
- The Lymphocyte in Hodgkin’s Disease: Has it Lost Its Way? (1984) (0)
- PATIENTS AND METHODS (1978) (0)
- Selective internal lymphoid irradiation with In-114m labelled lymphocytes: A preliminary report (1989) (0)
- Treatment of lymphoid cell malignancy using In-114m labelled lymphocytes. (1988) (0)
- Malignant Lymphomas other than Hodgkins's Disease (1981) (0)
- Mild hypogonadism and osteopaenia (1993) (0)
- Clinical use of interferon alfa-2b (intron-A): the Manchester experience. (1987) (0)
- Comparative intraperitonal pharmacokinetics of Cis-DDP, CHIP and CBDCA (1991) (0)
- Blood clearance of radio-labelled Cis-diamine-1, 1-cyclobutane dicarboxylato platinum (11)(CBDCA) (1983) (0)
- A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: A comparison of alternating combination chemotherapy given every four weeks for six cycles with the same dose of chemotherapy given at three week intervals (1996) (0)
- A clinical role for stem cell factor (SCF) in cancer patient management (1997) (0)
- In vivo depletion of human 06-alkylguanine-DNA alkyltransferase by temozolomide. (1994) (0)
- trial neutropenia in non-Hodgkin's lymphoma: a randomized controlled Granulocyte colony-stimulating factor to prevent dose-limiting (2011) (0)
- Selective targeting of In-114m for the treatment of lymphoid cell malignancy; from laboratory to the clinic. (1993) (0)
- 23. Autologous lymphocytes to target therapeutic radiation in patients with chronic lymphocytic leukaemia (1992) (0)
- Advances in Cancer Chemotherapy (1979) (0)
- Hodgkin's Disease (1981) (0)
- Combination chemotherapy foracutelymphoblastic leukaemia inadults (1978) (0)
- OP-28. Treatment of lymphoid cell malignancy with 114Inm-labelled autologous lymphocytes (1997) (0)
- The Year Book of Cancer, 1977 (1979) (0)
- Chronic Myeloid Leukaemia and Blastic Crisis. Series Haematologia, Vol. 8 (1977) (0)
- Glutathione content of ovarian tumour biopsies taken before and after cytotoxic chemotherapy (1993) (0)
- A randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma (2004) (0)
- Migration of leukaemic lymphocytes (chronic lymphocytic leukaemia) through a 3‐D collagen gel: a possible prognostic factor (1987) (0)
- Stem cell factor (r-metHuSCF) in combination with filgrastim (r-metHuG-CSF) enhances peripheral blood progenitor cell (PBPC) mobilisation following chemotherapy: A randomised study (1997) (0)
- Intensive combination chemotherapy for diffuse low grade non-Hodgkin's lymphomas of B- and T-cell lineage. (1993) (0)
- Human lymphocyte trafic assessed by In-111 oxide labelling: clinical observation. (1981) (0)
- Blood clearance of radiolabelled CBDCA (1983) (0)
- P-glycoprotein expression in ovarian tumour biopsies taken before or after cytotoxic chemotherapy (1992) (0)
- significance andclinicopathologi cal correlations (1989) (0)
- Relationship between 06-alkylguanine-DNA-alkyltransferase activity and 06-methyldeoxyguanosine formation after treatment with methylating agents in patients with malignant melanoma. (1993) (0)
- Autologous lymphocytes as vectors to target Indium-114m to sites of disease in Non-Hodgkin's lymphoma (1989) (0)
- Filgrastim (r-metHuG-CSF) in clinical practice. Basic and clinical oncology series/5 (1994) (0)
- The management of primary fallopian tube (1991) (0)
- Autologous lymphocytes to target therapeutic radiation in patients with chronic lymphocytic leukaemia (1991) (0)
- Selective lymphoid tissue irradiation using autologous lymphocytes in patients with chronic lymphocytic leukaemia (1992) (0)
- Rapid immunological reconstitution after high-dose chemotherapy and peripheral-blood stem-cell transplantation in high-grade non-hodgkin-lymphoma. (1994) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Derek Crowther?
Derek Crowther is affiliated with the following schools:
